The Technical Analyst
Pharming Group N.V. [PHAR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Pharming Group N.V. Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.60% €9.83
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 680.55 mill |
| EPS: | -0.160 |
| P/E: | -61.44 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 69.23 mill |
| Avg Daily Volume: | 0.0027 mill |
| RATING 2024-04-24 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -61.44 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -10.45x |
| Company: PE -61.44 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 9.30 - 10.36 ( +/- 5.39%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2004-05-27 | Camden Partners Strategic Fund Ii A Lp | Buy | 5 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 1 transactions |
| Buy: 5 000 | Sell: 0 |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - €9.83
Forecast 2: 16:00 - €9.83
Forecast 3: 16:00 - €9.83
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | €9.83 (1.60% ) |
| Volume | 0.0028 mill |
| Avg. Vol. | 0.0027 mill |
| % of Avg. Vol | 105.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PHAR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PHAR
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Last 10 Buy Signals
Latest Press Releases
2024-04-19 12:43:00 - Press Release
Pharming Group Announces The Repurchase Of Outstanding €125 Million Convertible Bonds Due 2025
Not for distribution in or into the united states or in or into australia, canada, japan, south africa or any other jurisdiction in which such distribution would be prohibited by applicable law.
2024-02-29 02:00:00 - Press Release
Pharming Group To Report Fourth Quarter And Full Year 2023 Financial Results On March 14
Leiden, the netherlands, february 29, 2024: pharming group n.v. (“pharming”) (euronext amsterdam: pharm/nasdaq: phar) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended december 31, on thursday, march 14, 2024.pharming will host a presentation for analysts and investors at 13:30 cet/08:30 am edt on march 14, 2024.to participate in the conference call, please register in advance using the link below. once registered, dial-in information and a unique pin will be provided, allowing access to the call.
2023-11-10 08:51:00 - Press Release
Pharming Group Provides Updates On Ema Regulatory Review Of Leniolisib Maa And Plans To File For Uk Regulatory Approval
Leiden, the netherlands, november 10, 2023: pharming group n.v. (“pharming” or “the company”) (euronext amsterdam: pharm/nasdaq: phar) announces that it has received a day 180 second list of outstanding issues (looi) from the european medicines agency's (ema) committee for human medicinal products (chmp) regarding its marketing authorisation application (maa) for leniolisib for adult and pediatric patients 12 years of age and older with apds, a rare primary immunodeficiency. based on the timetable included in the chmp day 180 second looi, and considering the chmp's decision to reschedule the ad-hoc expert group (aeg) meeting to the end of november, pharming now expects the chmp to issue its opinion on the leniolisib maa in the first quarter of 2024.
2023-08-24 02:00:00 - Press Release
Pharming Group To Participate In September Investor Conferences
Leiden, the netherlands , aug. 24, 2023 /prnewswire/ -- pharming group n.v. ("pharming") (euronext amsterdam: pharm/nasdaq: phar) announces that pharming's management will participate in the following investor conferences in the u.s. in the month of september: 2023 wells fargo healthcare conference, boston, september 6-8 sijmen de vries, chief executive officer, and michael levitan, vp investor relations and corporate communications, will participate in a fireside chat question and answer session on thursday, september 7 at 16:30 et/22:30 cet.
2023-08-09 01:00:00 - Press Release
Pharming Announces First Patient Enrolled In Phase Iii Clinical Trial Of Leniolisib For The Treatment Of Apds In Japan
Single-arm phase iii study in japan evaluating leniolisib in patients aged 12 years and older with apds, a rare primary immunodeficiency leiden, the netherlands , aug. 9, 2023 /prnewswire/ -- pharming group n.v. ("pharming" or "the company") (euronext amsterdam: pharm/nasdaq: phar) announces that the first patient has been enrolled in its phase iii clinical trial in japan evaluating leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (apds) in adult and pediatric patients 12 years of age and older.
Latest News
2024-04-22 06:31:04 - Zacks Investment Research
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2023-09-22 04:31:03 - Zacks Investment Research
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average.
2023-09-09 12:30:37 - Seeking Alpha
Pharming Group: Pipeline Progresses With APDS Phase 3 Initiation
Pharming Group NV is a biotechnology firm known for its unique approach to addressing rare and genetic diseases. The company's financials show growth in revenue, primarily driven by strong sales of their leading therapy, Ruconest. Pharming's expansion into organ transplantation fields adds a new dimension to their growth prospects, but challenges remain in gaining acceptance and assessing the impact on their income.
2023-08-24 02:00:00 - PRNewsWire
Pharming Group to participate in September investor conferences
LEIDEN, The Netherlands , Aug. 24, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the U.S. in the month of September: 2023 Wells Fargo Healthcare Conference, Boston, September 6-8 Sijmen de Vries, Chief Executive Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Thursday, September 7 at 16:30 ET/22:30 CET.
2023-08-06 04:51:08 - Seeking Alpha
Pharming Group N.V. (PHAR) Q2 2023 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR ) Q2 2023 Earnings Conference Call August 3, 2023 7:30 AM ET Company Participants Sijmen de Vries - Executive Director and Chief Executive Officer Anurag Relan - Chief Medical Officer Stephen Toor - Chief Commercial Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Christian Glennie - Stifel Joseph Pantginis - H.C.
2023-08-06 02:54:01 - Seeking Alpha
Pharming Group N.V. (PHGUF) Q2 2023 Earnings Call Transcript
Pharming Group N.V. (OTCPK:PHGUF) Q2 2023 Earnings Conference Call August 3, 2023 7:30 AM ET Company Participants Sijmen de Vries - CEO Anurag Relan - CMO Stephen Toor - CCO Jeroen Wakkerman - CFO Conference Call Participants Christian Glennie - Stifel Joe Pantginis - H.C.
2023-07-13 02:00:00 - PRNewsWire
Pharming Group to report second quarter and first half 2023 financial results on August 3
LEIDEN, The Netherlands , July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.
2023-05-31 11:13:53 - Proactive Investors
Tony's or Wonka? Choc maker issues three ‘golden shares'
Tony's Chocolonely, the chocolate maker, has issued three ‘golden shares' aimed at maintaining the group's sustainability pledge. The new governing structure is in place in case new shareholders or leadership try to steer the company away from its aim of ending inequality and exploitation in the chocolate industry.
2023-05-25 02:00:00 - PRNewsWire
Pharming Group to attend the following Investor Conferences in June
LEIDEN, The Netherlands , May 25, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following investor conferences in the month of June: Jefferies Healthcare Conference, New York, U.S., June 7 - 9 Pharming's CEO, Sijmen de Vries, will present on Thursday, June 8 at 10:30 EST / 16:30 CEST.
2023-05-11 14:44:06 - Seeking Alpha
Pharming Group N.V. (PHGUF) Q1 2023 Earnings Call Transcript
Pharming Group N.V. (OTCPK:PHGUF) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Sijmen de Vries – Chief Executive Officer Anurag Relan – Chief Medical Officer Stephen Toor – Chief Commercial Officer Jeroen Wakkerman – Chief Financial Officer Conference Call Participants Alistair Campbell – RBC Sushila Hernandez – VLK Simon Scholes – First Berlin Sijmen de Vries Good morning or good afternoon, ladies and gentlemen.